Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
Quest PharmaTech Inc.(”Quest” or the “Company”) today announced that it has signed a collaborative research agreement with the BC Cancer Agency (the “BCCA”) to develop a combination therapy for the treatment of lung cancer. The potential treatment will utilize the Company’s lead oncology product, SL052, with various immunotherapeutic agents. Research has shown that photodynamic therapy (PDT) can augment the therapeutic effects of immunomodulators such as antibodies, antigens, cytokines and immunoadjuvants in cancer patients.
This entry was posted on Monday, January 28th, 2008 at 2:49 pm and is filed under Research, Treatment. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.